Celldex Therapeutics, Inc. (CLDX)
$
22.68
+0.22 (0.97%)
Key metrics
Financial statements
Free cash flow per share
-2.5899
Market cap
1.5 Billion
Price to sales ratio
199.2090
Debt to equity
0.0049
Current ratio
21.6677
Income quality
0.9590
Average inventory
0
ROE
-0.2346
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Celldex Therapeutics, Inc. is a biopharmaceutical company engaged in the development of therapeutic monoclonal and bispecific antibodies aimed at treating a range of diseases. Its clinical development programs include CDX-0159, a Phase I monoclonal antibody that binds to the receptor tyrosine kinase KIT, effectively inhibiting its activity. Additionally, CDX-1140 is a human agonist monoclonal antibody that targets CD40, a crucial activator of immune response present on dendritic cells, macrophages, and B cells, as well as on various cancer cells. The company has also advanced CDX-527, a bispecific antibody employing proprietary active anti-PD-L1 and CD27 human antibodies, designed to promote anti-tumor T cell responses by coupling CD27 costimulation with the blockade of the PD-L1/PD-1 pathway. The operating expenses amount to $202,098,000.00 encompassing various operational costs incurred. The operating income ratio is -27.79 indicating the company's operational profitability margin. Furthermore, the company incurred an interest expense of $0.00 reflecting its debt servicing obligations, while reporting selling, general, and administrative expenses of $38,548,000.00 which illustrate its operational overhead costs. The gross profit stands at $7,020,000.00 highlighting the company's profitability from core operations. In the investment landscape, the stock is affordable at $22.68 making it suitable for budget-conscious investors. It boasts a high average trading volume of 988,748.00 indicating strong liquidity within the market. With a market capitalization of $1,505,820,456.00 the company is classified as a small-cap player, positioning itself as a key player in the Biotechnology industry and contributing significantly to the overall market landscape. Additionally, Celldex Therapeutics, Inc. operates within the Healthcare sector, driving innovation and growth, further enhancing its role and impact in the biopharmaceutical field.
Is Celldex Therapeutics, Inc. (CLDX) a good investment?
Investing in Celldex Therapeutics, Inc. (CLDX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Celldex Therapeutics, Inc. (CLDX)'s stock forecast?
Analysts predict Celldex Therapeutics, Inc. stock to fluctuate between $14.40 (low) and $47 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Celldex Therapeutics, Inc.'s market capitalization?
As of 2025-07-10, Celldex Therapeutics, Inc.'s market cap is $1,505,820,456, based on 66,394,200 outstanding shares.
How does Celldex Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Celldex Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Celldex Therapeutics, Inc. (CLDX) stock?
To buy Celldex Therapeutics, Inc. (CLDX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CLDX. Place an order (Market, Limit, etc.).
What is the best time to invest in Celldex Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Celldex Therapeutics, Inc. stock ever split?
Celldex Therapeutics, Inc.'s last stock split was 1:15 on 2019-02-11.
How did Celldex Therapeutics, Inc. perform in the last earnings report?
Revenue: $7,020,000 | EPS: -$2.45 | Growth: -16.10%.
Where can I find Celldex Therapeutics, Inc.'s investor relations reports?
Visit https://www.celldex.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Celldex Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Celldex Therapeutics, Inc. stock?
All-time high: $57.20 (2021-10-04) | All-time low: $14.40 (2025-04-09).
What are the key trends affecting Celldex Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company's Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1.
globenewswire.com
HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival.
globenewswire.com
HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company's Board of Directors.
zacks.com
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.57 per share a year ago.
https://thefly.com
Blueprint Medicines -3.19 (-3.52%) Celldex -2.21 (-8.33%)
globenewswire.com
HAMPTON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the Company has initiated a Phase 2 study of barzolvolimab in atopic dermatitis (AD) and that the study is actively enrolling patients. AD is one of the most common chronic inflammatory skin diseases, with a lifetime prevalence of up to 20% of the US population and a substantial impact on quality of life1. Mast cells are strongly implicated in all facets of AD pathophysiology and the fundamental processes that characterize AD, including epithelial barrier dysfunction, immune cell recruitment, neuroinflammation2 and multiple other mast cell-associated factors that correlate with disease severity. Activated mast cells are also found in increased numbers in lesional biopsies. Barzolvolimab is a humanized monoclonal antibody that specifically binds and blocks the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell.
globenewswire.com
HAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company's Phase 1a study of CDX-622 in healthy volunteers. CDX-622 is a bispecific antibody that targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells via stem cell factor (SCF) starvation.
globenewswire.com
HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:
zacks.com
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.81 per share a year ago.
globenewswire.com
HAMPTON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update.
See all news
